Catheter Precision, Inc. appears in FDA device records as the applicant behind VIVO, a Class II cardiovascular device classified as a programmable diagnostic computer under 21 CFR 870.1425 and product code DQK. The supplied portfolio snapshot, retrieved November 20, 2026, links one 510(k) record for the company, K261886, decided substantially equivalent on October 30, 2026. Earlier VIVO submissions in the numbered sources show the same trade name and classification, giving readers a dated view of how the filing identity has persisted across clearances. [1][2][5][7]
The 2026 VIVO clearance
K261886 covers a device listed as VIVO (9002), received June 5, 2026, and decided October 30, 2026 as substantially equivalent. The FDA record lists Catheter Precision, Inc. at 1670 Hwy. 160 W., Suite 205, Fort Mill, SC 29708, with a cardiovascular advisory committee, product code DQK, Class II, and a review type of Special. The agency database entry matches those dates and decision and notes the review was not conducted by a third party. [1][2]
The portfolio snapshot counts one linked record, a 510(k) with decision SESE, and the sample of one record carries the same decision. Those figures describe the supplied collection as of the retrieval date, not the company's total regulatory history or commercial position. [1]
Earlier VIVO submissions
A 2019 submission, K183195, names VIVO as the trade name, electrophysiological cardiac mapping system as the common name, and programmable diagnostic computer as the classification name, with Class II, Cardiovascular, product code DQK and 21 CFR 870.1425. The applicant is identified as Catheter Precision, Inc. at 500 International Drive Suite 333, Mt. Olive, New Jersey. [7]
A 2020 clearance letter for K200313 addresses Catheter Precision, Inc. and its CEO at 500 International Drive, Suite 255, Mt. Olive, New Jersey, for trade name VIVO, regulation 21 CFR 870.1425, Class II, product code DQK, and model number 9002. The letter states that VIVO is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician, and as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias. [5]
Documented product scope and labeling
Catheter Precision's product page describes VIVO as View Into Ventricular Onset and states an intended use as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation for idiopathic ventricular arrhythmias and for patients with structural heart disease undergoing catheter ablation of monomorphic ventricular tachycardia. The same page lists a United States address at 1670 Highway 160 West, Suite 205, Fort Mill, SC 29708, and an EU authorized representative, MedNet, in Münster, Germany. [3]
The company's product listing repeats the acquisition, analysis, display and storage description for VIVO. Its instructions-for-use page lists a VIVO System IFU for the United States at Rev 08 dated November 1, 2026, European language versions at Rev 11 dated March 3, 2026, and a separate VIVO Positioning Patch IFU for the United States at Rev 04. [4][9]
Applicant identity and related products
The company's about page describes Catheter Precision Inc. as developing medical devices intended to support physicians and hospitals, and cites decades of collective experience in bringing medical devices to market. That description is the company's own published characterization. [6]
A 2024 annual report filed with the SEC, whose registrant is not identified in the cited excerpt, states that FDA 510(k) clearance was received and that a limited commercial release of VIVO began in 2021 in the United States, and describes LockeT as that company's newest product, a suture retention device. The public documents do not establish that this filing belongs to Catheter Precision, Inc., so it should not be read as verified ownership, parentage or brand relationship. [8]

